Vaxart (OTCMKTS:VXRT – Get Free Report) will likely be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Vaxart to announce earnings of ($0.03) per share and revenue of $27.20 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:30 PM ET.
Vaxart (OTCMKTS:VXRT – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06. The company had revenue of $27.18 million during the quarter, compared to analysts’ expectations of $26.21 million. Vaxart had a return on equity of 53.04% and a net margin of 15.88%. On average, analysts expect Vaxart to post ($0.68) EPS for the current fiscal year and ($1.03) EPS for the next fiscal year.
Vaxart Price Performance
Shares of Vaxart stock traded down $0.01 during midday trading on Tuesday, hitting $0.40. The company had a trading volume of 177,363 shares, compared to its average volume of 475,369. The business’s 50 day simple moving average is $0.46 and its two-hundred day simple moving average is $0.58. The stock has a market cap of $97.26 million, a PE ratio of 2.49 and a beta of 1.05. Vaxart has a 1-year low of $0.30 and a 1-year high of $0.84.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised shares of Vaxart to a “hold” rating in a report on Thursday, July 9th. One research analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.
View Our Latest Stock Report on Vaxart
About Vaxart
Vaxart, Inc is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.
Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza.
Further Reading
- Five stocks we like better than Vaxart
- Republic Services Has the Momentum, But Waste Management Has Another Advantage
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
- Tempus AI Surges on Earnings Beat, But Can the Rally Last?
- MicroVision Pivots: Mapping New Ground Beyond Auto
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
